## **Electrophilic fluoride-18 from an 11 MeV proton cyclotron for radiolabeling of presynaptic dopaminergic PET tracers**

John Joseph Sunderland

The reliable production of  $(\$p{18}\F) F\$\sb2\$  from an 11 MeV proton cyclotron has been achieved through the implementation of two accelerator targets built to exploit the copious  $\$p{18}\O(p,n)\$p{18}\F$  cross-section. Yields of electrophilic ( $\$p{18}\F) F\$\sb2\$  from the targets reached deciCurie levels with specific activities approaching 3 Ci/mmole with 75 minute irradiations at 10  $\mu\A$ . Higher specific activities are expected with longer bombardments and increased beam current.

The targets, one nickel, the other with a gold-plated target chamber, have been tested for  $(\$\p{18}\F) F\$\p{2}\p{0}\p{18}\F) F\$\p{32}\p{0}\p{18}\F) F\$\p{32}\p{18}\P{1$ 

The behavior of these targets cannot be judged solely on the amount of reactive  $\left| 18\right|$ which elutes from the target; successful radiochemical synthesis utilizing this  $\left| 18\right|$ activity in a model reaction is the true test. Synthesis of 6- ( $\left| 18\right| F\right|$  fluoro-L-DOPA (6-FD) by the fluoro-demercuration method of Luxen served this purpose, testing the eletrophilic ( $\left| 18\right| F\right| F$ ) sb2\$ gas from the two targets and two irradiation protocols. Elution of Kr + ( $\left| 18\right| F\right| F$ ) sb2\$ from the two-step method achieved the expected 12% radiochemical yields from ( $\left| 18\right| F\right| F$ ) sb2, while experience with  $\left| 18\right| F$  activity eluted with oxygen from the single irradiation protocol suffered lower yields.

Solutions to problems associated with 6-FD studies for Positron Emission Tomography (PET) are addressed. A physiological compartmental model describing dopaminergic kinetics has been constructed to investigate PET's sensitivity to 6-FD metabolite formation. A high count rate, high efficiency plastic scintillator based automated blood sampler needed for input function collection is also reported. By resolution of these technical hurdles, pre-clinical PET imaging trials of 6-(\$\sp{18}\$F) fluoro-L-DOPA in normal subjects have been initiated at Wisconsin.